← Leaderboards

Frank S Hodi

Dana-Farber Cancer Inst

Google Scholar ↗PubMed ↗ORCID ↗

$11,927,265

Attributed

$23,334,669

Total exposure

8

Grants

3

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.3M · FY2010–25

$20M$15M$10M$5M$0

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$31,527,097 · 9

By mechanism

U24$16,455,371 · 1

U54$8,192,428 · 1

U01$2,909,935 · 1

R01$1,859,643 · 1

R21$1,385,011 · 2

P30$462,431 · 2

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Top investigators on “Immune”

Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
Bambra Strokes · Ppd Development Lp$526,656,217
Barton F Haynes · Duke University$470,748,611
Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Judith S. Currier · University Of California Los Angeles$334,425,492

Research focus

ImmuneMelanomaTumorMalignant NeoplasmsResponseCellsImmune ResponseLaboratoriesImmune Checkpoint BlockadeTherapy ResistantSuccessDana-Farber Cancer InstituteTreatment ResponsePre-ClinicalInstitutionPreclinical StudyImmunologyBiologyBraf GeneCollaborationsMissionNeoplasm MetastasisInter-InstitutionalClinical Research

Grant awards (36)

Cancer Immune Monitoring and Analysis Center$1,934,873

U24 · FY2025 · CA

Program 35: Melanoma$46,965

P30 · FY2025 · CA · contact PI

Cancer Immune Monitoring and Analysis Center$1,838,130

U24 · FY2024 · CA

Program 35: Melanoma$40,758

P30 · FY2024 · CA · contact PI

Cancer Immune Monitoring and Analysis Center$1,973,873

U24 · FY2023 · CA

3D Models of Immunotherapy$509,042

U01 · FY2021 · CA

Program 35: Melanoma$73,823

P30 · FY2021 · CA · contact PI

3D Models of Immunotherapy$556,812

U01 · FY2020 · CA

Program 35: Melanoma$73,710

P30 · FY2020 · CA · contact PI

Program 35: Melanoma$2,948

P30 · FY2020 · CA · contact PI

Biomaterials to Create T Cell Immunity$8,192,428

U54 · FY2019 · CA

3D Models of Immunotherapy$540,107

U01 · FY2019 · CA

Program 35: Melanoma$72,080

P30 · FY2019 · CA · contact PI

Program 35: Melanoma$6,167

P30 · FY2019 · CA · contact PI

3D Models of Immunotherapy$729,562

U01 · FY2018 · CA

Program 35: Melanoma$75,340

P30 · FY2018 · CA · contact PI

Program 35: Melanoma$11,429

P30 · FY2018 · CA · contact PI

Program 35: Melanoma$5,848

P30 · FY2018 · CA · contact PI

Program 35: Melanoma$5,123

P30 · FY2018 · CA · contact PI

Program 35: Melanoma$3,833

P30 · FY2018 · CA · contact PI

Program 35: Melanoma$1,602

P30 · FY2018 · CA · contact PI

Cancer Immune Monitoring and Analysis Center$10,708,495

U24 · FY2017 · CA

3D Models of Immunotherapy$574,412

U01 · FY2017 · CA

Program 35: Melanoma$42,805

P30 · FY2017 · CA · contact PI

Immunology of human malignant melanoma initiating cells$364,127

R01 · FY2016 · CA

Immunology of human malignant melanoma initiating cells$364,127

R01 · FY2015 · CA

Immunology of human malignant melanoma initiating cells$353,203

R01 · FY2014 · CA

Immunology of human malignant melanoma initiating cells$377,059

R01 · FY2013 · CA

Immunology of human malignant melanoma initiating cells$401,127

R01 · FY2012 · CA

Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma$323,248

R21 · FY2011 · CA · contact PI

Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma$332,407

R21 · FY2010 · CA · contact PI

CTLA-4 Blockade in GM-CSF Vaccinated Patients$364,678

R21 · FY2004 · CA

CTLA-4 Blockade in GM-CSF Vaccinated Patients$364,678

R21 · FY2003 · CA

MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION$87,426

K08 · FY2002 · CA

MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION$87,426

K08 · FY2001 · CA

MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION$87,426

K08 · FY2000 · CA